2019
DOI: 10.1016/j.bbi.2019.07.018
|View full text |Cite
|
Sign up to set email alerts
|

Abstract: Cognitive impairment is a major source of disability in schizophrenia and current antipsychotic drugs (APDs) have minimal efficacy for this symptom domain. Cannabidiol (CBD), the major non-intoxicating component of Cannabis sativa L., exhibits antipsychotic and neuroprotective properties. We recently reported the effects of CBD on cognition in male offspring of a maternal immune activation (polyinosinicpolycytidilic acid (poly I:C)) model relevant to the aetiology of schizophrenia; however, the effects of CBD … Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
2
1
1
1

Citation Types

1
15
2
1

Year Published

2020
2020
2023
2023

Publication Types

Select...
6
2

Relationship

1
7

Authors

Journals

citations
Cited by 32 publications
(19 citation statements)
references
References 107 publications
1
15
2
1
Order By: Relevance
“…Western blot procedures were conducted using standard methods used in our laboratory (Jimenez Naranjo et al, 2019; Millard et al, 2019; Osborne et al, 2019a, 2019b). DVC and MBH tissue was individually homogenised (left and right hemispheres combined) in NP-40 cell lysis buffer containing 0.5 mM β-glycerophosphate, 1 mM phenylmethane sulfonyl fluoride and 1% Protease Inhibitor Cocktail, as previously described (De Santis et al, 2018).…”
Section: Methodsmentioning
confidence: 99%
“…Western blot procedures were conducted using standard methods used in our laboratory (Jimenez Naranjo et al, 2019; Millard et al, 2019; Osborne et al, 2019a, 2019b). DVC and MBH tissue was individually homogenised (left and right hemispheres combined) in NP-40 cell lysis buffer containing 0.5 mM β-glycerophosphate, 1 mM phenylmethane sulfonyl fluoride and 1% Protease Inhibitor Cocktail, as previously described (De Santis et al, 2018).…”
Section: Methodsmentioning
confidence: 99%
“…Similarly, in female Poly I:C rats, chronic CBD in early adulthood attenuates recognition memory and social interaction deficits, and reverses the Poly I:C induced reduction in NMDA receptor binding in the PFC [176]. Poly I:C also increases GAD67 and parvalbumin interneuron protein levels in the hippocampus [176]. Interestingly, CBD administration control rats (i.e.…”
Section: Cannabinoids: Cbd Win Fatty Acid Amide Hydrolase Inhibitorsmentioning
confidence: 97%
“…Interestingly, CBD administration control rats (i.e. no Poly I:C treatment) reduces social interaction, as well as cannabinoid CB 1 receptor and NMDA receptor binding in the PFC, suggesting that CBD administration to healthy rats may have negative consequences on social behaviour and brain maturation in adulthood [176]. Together, this supports the antipsychotic potential of CBD for the treatment of cognitive and negative symptoms in schizophrenia but not healthy controls (review: [151]), and suggests CBD could be acting by reversing PFC CB 1 and NMDA receptor dysfunction and increasing GABA receptor function in the hippocampus, in a sex-specific manner.…”
Section: Cannabinoids: Cbd Win Fatty Acid Amide Hydrolase Inhibitorsmentioning
confidence: 99%
“…The body of studies presented here illustrates the general lack of comparability between pre-clinical and clinical studies. Of the clinical studies, only one ( 8) is reasonably comparable to just 4 (of 19) pre-clinical studies with respect to independent variables: CBD administered as a single drug to subjects with existing acute schizophrenia is comparable to CBD administration to rodent models that received subchronic/chronic NMDA receptor antagonist followed by drug washout (36,38) or to neurodevelopmental models (39)(40)(41). Nevertheless, the outcome measures in these pre-clinical studies are not easily comparable to those of the Leweke et al ( 8) study, except for deficits in social interaction, which are contemplated in the PANSS negative symptom subscale.…”
Section: From the Clinic To The Lab And Back Againmentioning
confidence: 99%